Trulicity

Chemical Namedulaglutide
Dosage FormInjection (subcutaneous; 0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, 4.5 mg/0.5 mL)
Drug ClassReceptor agonists
SystemEndocrine
CompanyEli Lilly and Company
Approval Year2014

Indication

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • Indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.
Last updated on 7/13/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Trulicity (dulaglutide) Prescribing Information.2021Eli Lilly and Company, Indianapolis, IN
Document TitleYearSource
Assessment report: Trulicity.2020EMA
Document TitleYearSource
Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.2022BMC Endocrine Disorders
Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.2021Diabetes Research and Clinical Practice
Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: a meta-analysis.2021International Journal of Clinical Practice
Efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus: a network meta-analysis.2021Advances in Therapy
Once-daily oral semaglutide versus injectable GLP-1 RAs in people with type 2 diabetes inadequately controlled on basal insulin: systematic review and network meta-analysis.2021Diabetes Therapy
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of 21 randomized controlled trials.2020Endocrine
Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis.2020Cardiovascular Diabetology
Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis.2020Annals of Internal Medicine
Gastrointestinal adverse events with insulin glargine/ lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: a network meta-analysis.2020Diabetes, Obesity & Metabolism
Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis.2019British Journal of Clinical Pharmacology
Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research.2017Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy